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S U M M A R Y
B A C K G R O U N D : There are no data comparing the 6–9
month oral three-drug Nix regimen (bedaquiline, pre-
tomanid and linezolid [BPaL]) to conventional regimens
containing bedaquiline (B, BDQ) and linezolid (L, LZD).
M E T H O D S : Six-month post end-of-treatment outcomes
were compared between Nix-TB (n ¼ 109) and 102
prospectively recruited extensively drug-resistant TB
patients who received an ~18-month BDQ-based
regimen (median of 8 drugs). A subset of patients
received BDQ and LZD (n ¼ 86), and a subgroup of
these (n¼75) served as individually matched controls in
a pairwise comparison to determine differences in
regimen efficacy.
R E S U LT S : Favourable outcomes (%) were significantly
better with BPaL than with the B–L-based combination
regimen (98/109, 89.9% vs. 56/86, 65.1%; adjusted
relative risk ratio [aRRR] 1.35; P , 0.001) and in the
matched pairwise analysis (67/75, 89.3% vs. 48/75,
64.0%; aRRR 1.39; P ¼ 0.001), despite significantly
higher baseline bacterial load and prior second-line drug
exposure in the BPaL cohort. Time to culture conversion
(P , 0.001), time to unfavourable outcome (P , 0.01)
and time to death (P , 0.03) were significantly better or
lower with BPaL than the B-L-based combinations.
C O N C L U S I O N : The BPaL regimen (and hence substitu-
tion of multiple other drugs by pretomanid and/or
higher starting-dose LZD) may improve outcomes in
drug-resistant TB patients with poor prognostic fea-
tures. However, prospective controlled studies are
required to definitively answer this question.
K E Y W O R D S : drug resistance; tuberculosis; drug treat-
ment; BPaL; bedaquiline; linezolid
TB IS THE FOREMOST INFECTIOUS DISEASE
globally and almost a billion people have died due to
TB over the past two centuries.1 Control efforts in
several parts of the world have been subverted by the
growing incidence of multidrug-resistant TB (MDR-
TB) and extensively drug-resistant TB (XDR-TB).2
The global burden of MDR- and XDR-TB taken
together in 2018 was estimated at ~half a million
cases and the number of confirmed cases has nearly
doubled in the last 5 years.2,3 The 2019 WHO Global
TB Report estimated favourable outcome rates for
MDR-TB to be ~56%, and drug-resistant TB (DR-
TB) as a whole accounted for ~25% of global TB
mortality.3 The introduction of novel and repurposed
drugs such as bedaquiline (BDQ) and linezolid (LZD)
appears to improve mortality and outcomes.4–10
However, even with the use of these newer agents,
unfavourable outcome rates in MDR-TB remain at
~25% and at ~35% for XDR-TB.4–6 Treatment
options therefore remain limited. It should be noted
that only one in three cases of DR-TB in 2018
received treatment.3 Furthermore, improved out-
comes were only achieved in selected studies and
regions, while the unfavourable outcome rate in 2018
globally remained dismal, at~45% for MDR-TB and
at ~60% for XDR-TB.3 Thus, there is an urgent need
for alternative and improved regimens, particularly
for XDR-TB. Although the optimal duration of a
specific drug combination or treatment regimen for
DR-TB remains unclear, a longer duration of treat-
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ment (18–20 months) and higher pill burden has been
associated with poor adherence.2 Hence, there is a
pressing need for shorter regimens with increased
effectiveness and reduced pill burden. This is espe-
cially so in patients with poorer prognosis, including
those with XDR-TB and treatment-intolerant or
failed MDR-TB.
Pretomanid (Pa, PTM), a nitro-imidazooxazine
that blocks mycobacterial cell wall production and
increases nitric oxide release, was recently approved
by the US Food and Drug Administration (US FDA)
as part of a combination regimen BPaL (with BDQ
and LZD) for the treatment of adults with pulmonary
XDR-TB, or treatment-intolerant or non-responsive
MDR-TB. This was based in part on a 90% treatment
success rate in the first 107 patients followed to the
primary endpoint in a Phase 3 single-arm clinical
study – known as the Nix-TB trial.11 Preclinical data
highlighted the individual contribution of all three
drugs (BDQ, PTM and LZD) in achieving the efficacy
of the three-drug regimen.12 Furthermore, PTM
demonstrated dose-related antimycobacterial activity
in a 2-week monotherapy clinical study in drug-
susceptible TB patients.13 However, Nix-TB was an
open-label study without a control arm. Thus, to date
there are no clinical data comparing the efficacy of
the BPaL regimen to BDQ and LZD-based (B–L)
regimens containing companion drugs but without
PTM. To address this question, we compared
outcomes from the Nix-TB cohort to a prospectively
recruited clinical registry-based cohort of patients
with XDR-TB from Cape Town, South Africa.4
MATERIALS AND METHODS
Study design and participants
A cohort-comparison study with prospective follow-
up was performed post-hoc between two cohorts:
the Nix-TB cohort (BPaL population) and the XDR-
TB cohort (BDQ- and mostly LZD-treated popula-
tion with companion drugs). The Nix-TB cohort
consisted of 109 patients enrolled in a prospective
intervention trial between April 2015 and Novem-
ber 2017 from three study sites in South Africa:
Sizwe Tropical Disease Hospital, Johannesburg;
Task Applied Science at Brooklyn Chest Hospital,
Cape Town; and King DinuZulu Hospital Complex
in Durban, South Africa. After obtaining informed
consent, the comparator cohort was enrolled be-
tween August 2013 and August 2018 in a prospec-
tively recruited observational trial from Brooklyn
Chest Hospital, which is the designated XDR-TB
treatment centre in the Western Cape Province of
South Africa. Treatment was directly observed by
trained health workers (details have been pub-
lished).4 Patients from both cohorts were treated in
a hospital setting for a variable duration of their
treatment and had microbiologically confirmed TB
with isolates showing MDR-TB or XDR-TB.
Demographic and clinical information was ob-
tained by trained healthcare workers. BPaL cohort
patients were actively monitored, and their data
collected in real time. For the comparator group,
information was regularly extracted by a trained
healthcare worker from patient records and associat-
ed healthcare and laboratory systems. The demo-
graphic variables collected included age, sex and
body weight at diagnosis. The clinical variables
collected included HIV status, CD4 count at baseline
for those coinfected with HIV, smear status at
baseline, medications used in the regimen and adverse
events. Further elaboration of the cohorts and
treatment-related adverse events have been published
in the papers describing each cohort.4,11
Ethical approval was obtained from the relevant
human research ethics committees (HRECs) for both
cohorts (University of Cape Town HREC, Cape
Town, South Africa; HREC reference 038/2008;
and Pharma Ethics (123 Amcor Road, Lyttlelon
Manor, Pretoria, South Africa; no14065930).
Treatment regimens
The Nix-TB regimen comprised BDQ, PTM and LZD
(BPaL). The first 44 participants were started on LZD
600 mg twice daily, and the remaining 65 were
started on 1200 mg once daily with dosage reduc-
tions, interruptions and discontinuation allowed for
LZD, depending on tolerability. The three medica-
tions were prescribed for 6 months in the majority of
the population; treatment was prolonged to 9 months
as per the protocol in two participants whose sputum
had not culture converted to negative by Month 4 of
treatment.
The comparator population received a regimen in
line with the South African National TB Programme
(NTP). For the selected population, this included a
core comprising BDQ (100%) and LZD (84%) (at a
South African standard dose of 600 mg daily). These
patients also often received pyrazinamide (98%),
clofazimine (96%), levofloxacin (91%), para-amino-
salicylic acid (PAS) (90%) and terizidone (89%). The
median number of medications prescribed in this
population was 8. The aimed duration of treatment in
this population was 18–24 months, with a median
duration of 18 months in those who completed the
regimen.
Outcomes
The primary treatment efficacy endpoint in the Nix-
TB population was defined (as per protocol) as the
incidence of bacteriological failure or relapse, or
clinical failure at 6 months after the end of treatment.
Favourable outcomes for this analysis included
patients with a negative culture status at 6 months
after the end of treatment, those who had not already
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been classified as having an unfavourable outcome
and those whose last positive culture result was
followed by at least two negative culture results.
Unfavourable outcomes included all patients who
died, those who relapsed prior to 6 months after
treatment completion (defined for this analysis as
‘‘treatment failures’’) or those who were lost to
follow-up (LTFU) or those who withdrew from the
trial.
Treatment outcomes for the comparator popula-
tion were defined according to the adapted 2013
WHO criteria as modified by Furin et al.14,15
Favourable outcomes included patients who achieved
cure (defined as treatment completed without evi-
dence of failure, with three or more consecutive
negative sputum culture results after the intensive
phase of treatment) or treatment completion. Unfav-
ourable outcomes were assigned to patients who died,
failed treatment, defaulted or were LTFU.4 The
assessment time-point in the comparator population
was 24 months after the start of treatment with the
BDQ-based regimen (or 6 months post-end-of treat-
ment as most patients received ~18 months of
therapy).
RESULTS
Demographic and clinical characteristics
The baseline characteristics between the two popula-
tions are shown in Table 1, in Supplementary Table
S1A for the subgroup that received both BDQ and
LZD, and in Supplementary Table S1B when these
participants were matched for demographic features
and HIV status. Antiretroviral coverage was 100% in
both cohorts.
Treatment outcomes in the different comparison
groups
Overall comparison (Comparison 1)
As shown in Table 2A and 2C, in the overall
comparison between the groups the favourable
outcome rate (%) was significantly better in those
on the BPaL regimen than in the BDQ-based XDR-
TB cohort (P , 0.001; Table 2). Time to culture
conversion (significantly more rapid with BPaL, P ,
0.001), and time to unfavourable outcome and time
to death (significantly longer with BPaL, P¼ 0.0023
and P¼ 0.027) are shown in Figures 2A, 2B and 2C,
respectively.
The demographic data for those who died in both
cohorts are shown in Supplementary Table S4A. The
overall relative risk ratio (RRR) for death in the Nix-
TB vs. the XDR-TB comparator cohort is shown in
Supplementary Table S4B and the RRR for death
stratified by CD4 count is shown in Supplementary
Table S4C.
Patients who received bedaquiline and linezolid
(Comparison 2)
The Nix-TB cohort was also compared to the
subgroup of participants from the XDR-TB compar-
ator cohort who received BDQ and LZD as part of







n/N (%) P value
Sex 0.12
Female 52/109 (47.7) 37/102 (36.3)
Male 57/109 (52.3) 65/102 (63.7)
Age at treatment initiation, years, mean 6 SD 35.6 6 10.1 36.8 6 11.2 0.41
Weight, kg, mean 6 SD 56.9 6 15.0 53.1 6 10.0 0.03
Baseline smear results ,0.01
Negative 31/109 (28.4) 74/102 (72.5)
Positive 78/109 (71.6) 28/102 (27.5)
HIV status 1.00
Negative 53/109 (48.6) 50/102 (49.0)
Positive 56/109 (51.4) 52/102 (51.0)
CD4 count at baseline, cells/mm3 median [IQR] 406 [282–632] 129 [56–283] ,0.01
Duration of second-line drug exposure prior to
interventional treatment initiation, weeks
0.011
Not available 0 11
8 21/109 (19.3) 32/91 (35.2)
.8 88/109 (80.7) 59/91 (64.8)
LZD ,0.01
No 0/109 (0.0) 16/102 (15.7)
Yes 109/109 (100.0) 86/102 (84.3)
* Relevant demographic data comparisons for Comparison 2 (patients who received BDQ and LZD) are shown in
Supplementary Table S1A and for Comparison 3 (patients who received BDQ and LZD, and who were matched for
demographic characteristics and HIV status) are shown in Supplementary Table S1B.
XDR-TB ¼ extensively drug-resistant TB; SD ¼ standard deviation; IQR ¼ interquartile range; LZD ¼ linezolid; BDQ ¼
bedaquiline.
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their treatment regimen (Comparison 2; Figure 1). As
outlined in Table 3A and 3C, the Nix-TB population
had a better favourable outcome (%) compared to
this XDR-TB comparator subgroup (P , 0.001). The
breakdown of unfavourable outcomes is shown in
Table 3B.
Matched controls (Comparison 3)
In a further analysis, we compared those who
received BDQ and LZD in the two population sub-
samples individually matched by sex, age, body
weight and HIV status at baseline (Figure 1). We
aimed for a 1:1 Nix-TB to comparator ratio.
Consequently, the two sub-samples included 75
Nix-TB participants and 75 matched controls. There
were minimal differences between the two popula-
tions (Supplementary Table S1B).
As outlined in Table 4A, 4B and 4C the Nix-TB-
population had a better favourable outcome (%)
compared to the matched controls in the XDR-TB
comparator population (P¼ 0.001).
When smear microscopy status was added to the
matching criteria, the sample size decreased to 54
Table 2 Comparison 1: overall outcome comparison between





n/N (%) P value*
A) Favourable vs. unfavourable outcomes
Favourable 98/109 (89.9) 66/102 (64.7)
Unfavourable 11/109 (10.1) 36/102 (35.3)
Total 109 102 ,0.01
B) Unfavourable outcomes
Death 7/109 (6.4) 19/102 (18.6)
Default 0/109 (0) 1/102 (0.9)
Treatment failure 2/109 (1.8) 5/102 (4.9)
Withdrawn 1/109 (0.9) 0/102 (0)
Lost to follow-up 1/109 (0.9) 11/102 (10.7)
Total 11/109 (10.1) 36/102 (35.3) ,0.01
C) Relative risk ratio for a favourable outcome in the Nix vs. the
XDR-TB comparator populations
Nix-TB/XDR-TB
Risk ratio (95% CI) P value*
Unadjusted 1.39 (1.19–1.62) ,0.001
Adjusted† 1.35 (1.14–1.59) ,0.001
* Derived from the likelihood ratio v2 test.
† Adjusted for sex, HIV status, age (years), weight (kg) and smear microscopy
status.
XDR-TB¼ extensively drug-resistant TB; CI¼ confidence interval.
Figure 1 Study overview and analysis plan. XDR-TB¼ extensively drug-resistant TB; MDR-TB¼multidrug-resistant TB; BPaL¼ BDQ,
pretomanid and LZD; BDQ¼ bedaquiline; LZD¼ linezolid.
Table 3 Comparison 2: outcome comparison between Nix-TB






n/N (%) P value*
A) Favourable vs. unfavourable outcomes
Favourable 98/109 (89.9) 56/86 (65.1)
Unfavourable 11/109 (10.1) 30/86 (34.9)
Total 109 86 ,0.01
B) Unfavourable outcomes
Death 7/109 (6.4) 15/86 (17.4)
Default 0/109 (0) 1/86 (1.2)
Treatment failure 2/109 (1.8) 4/86 (4.7)
Withdrawn 1/109 (0.9) 0/86 (0)
Lost to follow-up 1/109 (0.9) 9/86 (10.5)
Total 11/109 (10.1) 29/86 (33.7) ,0.01
C) Relative risk ratio for a favourable outcome in the Nix vs. the
XDR-TB comparator populations
Nix-TB/XDR-TB
Risk ratio (95% CI) P value*
Unadjusted 1.38 (1.17–1.63) ,0.001
Adjusted† 1.35 (1.13–1.60) ,0.001
* Derived from the likelihood ratio v2 test.
† Adjusted for sex, HIV status, age (years), weight (kg) and smear microscopy
status.
XDR-TB¼ extensively drug-resistant TB; CI¼ confidence interval.
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participants. The demographic data of this subgroup
are shown in Supplementary Table S2 in the online
supplement. As shown in Supplementary Table S3A
and S3C, the Nix-TB-population showed a better
favourable outcome (%) than matched controls in the
XDR-TB comparator population (P¼ 0.037).
HIV-infected vs. non-HIV-infected persons
The frequency of HIV infection (%) was similar for
the Nix-TB cohort and the XDR-TB comparator
cohort (56/109, 51.4% vs. 52/102, 51.0%). HIV-
infected persons in the Nix-TB cohort had a better
favourable outcome (%) than the XDR-TB compar-
ator cohort (P¼ 0.011; Table 5A). A similar pattern
was seen in non-HIV-infected persons (P ¼ 0.007;
Table 5B). The RRR stratified by CD4 count for those
who were HIV-infected is shown in Table 5C.
DISCUSSION
We performed a cohort-comparison study with
prospective follow-up comparing patients with
XDR-TB and treatment intolerant MDR-TB who
received the 6- to 9-month BPaL regimen (starting
dose of 1200 mg LZD daily) to patients with XDR-
TB who received an 18- to 20-month 8-drug (median)
B–L-based regimen (starting dose of 600 mg LZD
daily). The key finding was that the patients receiving
the BPaL regimen had a significantly better 6-month
post-treatment outcome than those on the B–L-based
regimen when controls were matched for demograph-
Figure 2 Kaplan–Meier curves depicting A) culture conversion
probability: time to culture conversion for participants in the Nix-TB
(n¼90) and the XDR-TB comparator cohort (n¼63) censored at 52
weeks;* B) unfavourable outcome probability: time to unfavour-
able outcome in the total Nix-TB (n¼ 109) and the total XDR-TB
comparator population (n ¼ 102) censored at 52 weeks; and C)
probability of death: time to death for all participants in the Nix-TB
(n¼109) and XDR-TB comparator (n¼102) cohorts censored at 52
weeks. *Only patients who were culture-positive at baseline were
included in the analysis. Participants who died but did not culture
convert were also included in this analysis. Solid lines represent time
to event and the shaded areas represent the 95% CIs. XDR-TB¼
extensively drug-resistant TB; CI¼ confidence interval.
Table 4 Comparison 3: outcome comparison between Nix-TB
and XDR-TB comparator populations who received bedaquiline






n/N (%) P value*
A) Favourable vs. unfavourable outcomes
Favourable 67/75 (89.3) 48/75 (64.0)
Unfavourable 8/75 (10.7) 27/75 (36.0)
Total 75 75 ,0.01
B) Unfavourable outcomes
Death 4/75 (5.5) 15/75(20.0)
Default 0/75 (0) 1/75 (1.3)
Treatment failure 2/75 (2.7) 2/75 (2.7)
Withdrawn 1/75(1.3) 0/75(0)
Lost to follow-up 1/75 (1.3) 7/75 (12.0)
Total 8/75 (10.7) 25/75 (33.3) ,0.01
C)
Nix-TB/XDR-TB
Risk ratio (95% CI) P value*
Unadjusted 1.40 (1.16, 1.68) ,0.001
Adjusted† 1.39 (1.14, 1.69) 0.001
* Derived from the likelihood ratio v2 test.
† Adjusted for sex, HIV status, age (years), weight (kg) and smear microscopy
status.
XDR-TB¼ extensively drug-resistant TB; CI¼ confidence interval.
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ic characteristics and HIV status, and outcomes were
adjusted for smear-related mycobacterial disease
burden. This was the case even though the Nix-TB
cohort included a significant proportion of DR-TB
treatment failures with a significantly higher rate of
prior second-line drug exposure. Nix-TB patients also
received a median of five fewer drugs than the XDR-
TB comparator cohort. Thus, although the baseline
characteristics of the cohorts were not entirely
concordant (which we acknowledge and discuss in
the limitations section below), the Nix-TB cohort
likely had worse prognostic features but potentially
better outcomes. The outcome benefit of BPaL was
seen in both HIV-infected and non-infected persons
(the effect of CD4 count is discussed below).
Treatment outcome comparisons were made at 6
months after treatment completion in the Nix-TB
population and up to 24 months post-treatment
initiation in the comparator cohort. Despite the
difference in assessment timing relative to treatment
initiation, 12-month post-treatment initiation out-
comes have been shown to correlate well with longer-
term outcomes and even 6-month culture positivity
rates correlate highly with unfavourable out-
comes.4,16,17 Indeed, it appears that even at 24
months post-treatment completion, the outcome
benefit was sustained.
The outcome benefit with the Nix-TB regimen was
seen despite 1) the shorter duration of treatment (~6
months vs. 18–20-month BDQ-LZD regimen) in
patients with XDR-TB; 2) the fact that most patients
in the Nix-TB trial were on prior treatment with
second-line drugs; and that 3) on average, five fewer
drugs compared to the XDR-TB comparator cohort
were administered. The outcome benefit of the Nix-
TB regimen was sustained even after adjustment for
prognostic characteristics such as HIV status (CD4 is
discussed below under limitations), age, weight and
mycobacterial disease burden (smear status that was
differentially distributed between the groups and
adjusted for in the analysis), etc. Indeed, PTM
showed good early bactericidal activity (EBA) in
two-phase 2A studies and murine studies, indicating
that BPaL performed better than any two-drug
combinations of BDQ, LZD and/or PTM.12 The
starting LZD dose of 1200 mg may have added to the






n (%) P value*
A) HIV-infected
Favourable 50 (89.3) 33 (63.5)
Unfavourable 6 (10.7) 19 (36.5)
Total 56 52 ,0.01
Nix-TB/comparator
Risk ratio (95% CI) P value*
Unadjusted 1.41 (1.12–1.76) 0.003






n (%) P value*
Favourable 48 (90.6) 33 (66.0)
Unfavourable 5 (9.4) 17 (34.0)
Total 53 50 ,0.01
Nix-TB/comparator
Risk ratio (95% CI) P value*
Unadjusted 1.37 (1.10–1.70) 0.004
Adjusted† 1.35 (1.08–1.67) 0.007
C) CD4, cells/mm3‡
Nix-TB/comparator
Risk ratio (95% CI) P value*
CD4 , 200 Unadjusted 1.47 (1.00–2.17) 0.05
CD4 , 200 Adjusted† 1.37 (0.91–2.08) 0.13
CD4 . 200 Unadjusted 1.36 (0.96–1.91) 0.079
CD4 . 200 Adjusted† 1.24 (0.85–1.80) 0.27
* Derived from the likelihood ratio v2 test.
† Adjusted for sex, age (years), weight (kg) and smear microscopy status.
‡ Due to the small number of participants with a CD4 count ,200 cells/lL (seven in the Nix-TB population and only one
with an unfavourable outcome in the same population), we were unable to meaningfully adjust for CD4 count or
perform further analyses.
XDR-TB¼ extensively drug-resistant TB; CI¼ confidence interval.
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efficacy of the regimen, as the EBA-associated
mycobactericidal effect of LZD was shown to be
dose-dependent in drug-susceptible TB.18 A 1200 mg
daily LZD dose may be associated with better
outcomes, and this dose is also likely to have the best
effect in terms of preventing resistance amplification
based on pharmacokinetic studies (given the higher
bactericidal activity).12,19 Nevertheless, drug efficacy
is likely to be related to a number of factors, including
population-level heterogeneity in AUC/MIC (area
under the curve/minimum inhibitory concentration)
targets, host-related factors (absorption, metabolism,
genetics, etc.) and intracavitory and lesion-specific
drug penetration, among others. There is also
possible synergistic activity between BDQ, PTM
and LZD.12,20,21
While these are the first published comparative
data of BPaL vs. a B-L-containing regimen in patients
with DR-TB, there are a number of implications and
limitations to our study. 1) The prospective Nix-TB
study was not a controlled one and the cohorts being
compared were recruited at time periods that did not
fully overlap, and in a different context (one was a
prospective cohort study, the other was a prospective
Phase 3 registration study performed under strict
Good Clinical Practice conditions). The sample size
was also limited. However, both cohorts were
prospectively recruited, and both recruited HIV-
infected and non-infected patients. Both were per-
formed in the same geographical setting, i.e., South
Africa (and many from the same facility in Cape
Town), and the sample size was large enough to
demonstrate significant differences in regimen effica-
cy. Furthermore, the efficacy benefit was seen even
when matched controls (matched for BDQ and LZD
usage, demographic characteristics and HIV status)
were compared, and when the findings were adjusted
for prognostic characteristics such as weight, HIV
status and baseline bacterial load. Thus, although the
baseline characteristics had some differences (further
matching would have substantially reduced sample
size and hence, power), we adjusted our analysis for
these differences as best as we could. Indeed, we
performed a separate analysis matching for smear
status in a smaller group of 54 paired patients
(Supplementary Table S2), which showed the same
pattern of outcome benefit. 2) Related to this latter
point, median CD4 count was significantly lower in
HIV-infected persons in the XDR-TB group, thus
potentially confounding our results. However, we
could not perform propensity matching for this
characteristic, given the effect on the sample size
(matching would have produced 28 matched pairs,
severely reducing power), and we could not adjust for
CD4 in the HIVoutcome analysis (Table 5) because of
limited power (only one person in the Nix-TB cohort
had an unfavourable outcome with a CD4 , 200
cells/mm3). However, we did further stratify analysis
by CD4 count (Table 5), and if the adjusted risk ratio
in those with advanced immunosuppression was a
major driver, we would have likely seen a significant
difference in this stratum (to note, the effect we see is
in the opposite direction, i.e., in favour of Nix despite
the higher frequency of advanced immunosuppres-
sion in the XDR-TB group). 3) The study findings
may not be generalisable to other settings where HIV
is not endemic and the strain heterogeneity is different
due to the abovementioned drawbacks. 4) Both
regimens were of different durations (6 months vs.
18–24 months of intended treatment), and the
primary endpoint was at 6 months post-treatment
completion for the Nix-TB cohort and at 24 months
post-treatment initiation for the XDR-TB compara-
tor cohort. To note, outcome data were assessed, on
average, at 6 months post-treatment completion in
both groups. However, both 6- and 12-month
outcomes have been shown to correlate very well
with long-term outcomes in patients with XDR-
TB.4,7 Indeed, upon reviewing 47 Nix-TB partici-
pants who were enrolled and had the opportunity to
reach the 24-month post-treatment completion time-
point, only one additional unfavourable outcome, a
relapse, has been recorded. This degree of follow-up
after treatment is greater than that of the comparator
group. Furthermore, the outcome benefits seen with
the BPaL regimen is even more striking, given that the
treatment regimen was of only 6 months’ duration in
all but two patients. Another aspect related to the
regimen is that comparative BDQ and LZD suscep-
tibility testing was not performed; however, stan-
dardised assays were not programmatically available
at the time, and we showed that background
resistance to LZD and BDQ was extremely low in
this population.1 Furthermore, there may have been
differential susceptibility to oflaxacin vs. levoflox-
acin, which may have impacted outcomes. 5) The
potentially better outcomes seen in the BPaL regimen
may be partly or completely due to the Hawthorne
effect, given that this was performed under strict
research study conditions.22 Indeed, in the STREAM
(Standard Treatment Regimen of Anti-tuberculosis
Drugs for Patients With MDR-TB) I study the
favourable outcome rate for MDR-TB patients even
with a non-BDQ and non-LZD injectable-based
regimen was as high as 83%.23 6) The possibility of
a survival bias effect cannot be ruled out, i.e., Nix-TB
self-selected for survivors and patients with the most
severe disease were not included. However, Nix-TB
enrolled patients with poor prognostic features (those
who had failed MDR- or XDR-TB treatment), and
the same bias applied to the XDR-TB comparator
group, as only those initiating treatment were
included in the cohort. 7) We did not perform safety
comparisons between the groups. However, drug
toxicity profiles are reported in the parent manu-
scripts,4,11 and different intensities of safety moni-
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toring and significant observation bias precluded
comparison of adverse events and laboratory abnor-
malities; nevertheless, safety issues that were fatal or
led to discontinuation are incorporated in the
outcome measures. Finally, it is possible that the
outcome effect seen could have been influenced by
disease extent (extensive parenchymal disease and
cavitation), prior drug treatment exposure, and
differential culture negativity at baseline. However,
demographic baseline characteristics were similar,
and we adjusted for weight and baseline bacterial
burden (an important prognostic feature) in the risk
ratio analysis. Furthermore, we compared compara-
tive drivers of mortality in the cohorts (see online
Supplementary Data) and accounted for CD4 count
differences in the HIV analysis (as outlined above)
given that the level of immunosuppression was higher
in the XDR-TB comparator group.
In conclusion, in this cohort-comparison study
with prospective follow-up, the ~6-month BPaL
regimen showed potentially better 6-month post-
treatment outcomes in patients with XDR-TB com-
pared to an ~18-month B–L-based regimen. These
data, despite the limitations noted, may lend support
to the conclusion that PTM likely plays a significant
contributory role to the efficacy seen with the BPaL
regimen. However, given the limitations of the
current analysis, further controlled studies are re-
quired to definitively answer the question.
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R É S U M É
C O N T E X T E : Il n’y a pas de données comparant les
protocoles oraux de 6–9 mois associant trois
médicaments (bédaquiline, prétomanide et linézolide
[BPaL]) aux protocoles conventionnels contenant de la
bédaquiline (B, BDQ) et du linézolide (L, LZD).
M É T H O D E : On a comparé les résultats 6 mois après la
fin du traitement entre Nix-TB (n¼109) et 102 patients
TB recrutés prospectivement qui ont reçu un protocole
de BDQ d’environ 18 mois (médiane de 8 médicaments).
Un sous ensemble de patients a reçu de la BDQ et du
LZD (n¼86) et un sous-groupe de ces derniers (n¼75) a
servi de témoins appariés individuellement pour des
comparaisons par paires afin de déterminer les
différences d’efficacité du protocole.
R É S U LTAT S : Des résultats favorables (%) ont été
significativement meilleurs avec BPaL qu’avec le
protocole combiné basé sur B-L (98/109, 89,9%
contre 56/86, 65,1% ; rapport de risque relatif ajusté
[RRRa] 1,35 ; P , 0,001) et dans l’analyse par paires
(67/75, 89,3% contre 48/75, 64,0% ; RRRa 1,39 ; P¼
0,001) malgré une charge bactérienne initiale
significativement plus élevée et une exposition
préalable aux médicaments de deuxième ligne. Le délai
de conversion de la culture (P , 0,001), le délai de
résultats défavorables (P , 0,01) et de décès (P , 0,03)
ont été significativement meilleurs ou plus bas avec BPaL
comparés à la combinaison à base de BL.
C O N C L U S I O N : Le protocole BPaL (et donc la
substitution de multiples autres médicaments par le
prétomanide et/une dose de départ plus élevée de LZD)
pourrait améliorer les résultats des patients TB résistante
ayant des facteurs de pronostic négatifs. Des études
prospectives contrôlées sont cependant requises pour
répondre définitivement à cette question.
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